HugoScore hugoscore.org

Evidence and research literacy tool

Noah AI

Noah AI supports direct research questions, scope clarification, and editable evidence. These patient-accessible functions must be distinguished from inferred institutional uses. The evidence does not establish universal absence of recourse or dominant downstream effects.

Document-based draft Read full report Open directory

Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.

Mixed6 of 12 agency checks metDocument-based draft. Independent confirmation incomplete; not product-tested.How categories work

Agency checklist · October 30, 2026

Mixed 6 of 12 yes

Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.

Assessed function: Noah X, the publicly accessible Noah AI professional research agent, assessed for a patient's direct research use. Hypothetical downstream pharma-industry effects are not scored.

A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.

  • Public documents do not establish actual product behavior.
  • The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
QuestionAnswerEvidence / reviewSource and reasoning
1. Told it is AIYesdocumented
Not independently replicated
Meet Noah X, an AI agent built for the way you work. Source

The privacy notice also says the Services include products 'powered by artificial intelligence'.

2. Operator and model maker namedNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

TOLONGEVITY PTE. LTD. (dba Noah AI) is named as operator. No model maker is named for Noah X, and the pages describe the 'Noah World Model' without saying whether third-party LLMs are used.

3. Patient chooses to use itYesdocumented
Not independently replicated
Try Noah X for Free Source

A user registers and chooses to use it. The product targets individual professionals and enterprises, so a patient using it is off-label.

4. Patient sets the taskYesdocumented
Not independently replicated
Ask it yourself. A biomedical generalist for your daily work, from discovery through commercial. Source

The user sets the question for this research agent.

5. Patient can decline or stopYesdocumented
Not independently replicated
Try Noah X for Free Source

Self-started tool per the Q3 source, no care depends on it.

6. Patient sees the AI outputYesdocumented
Not independently replicated
Trace every claim to its filing, trial, paper, or patent in one click. Source

The user sees cited answers to their own questions. The output is research content, not an output about the patient.

7. Patient can correct or challengeNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

The policy lists a right to correct inaccuracies in personal data, conditional on residence. No route to contest Noah X output.

8. Patient can get a copyNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

The notice says users 'may have the right' to a copy depending on state or region, by emailing [email protected]. No general export is documented.

9. Patient can deleteNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Section 17 gives an email route to delete personal information, but only 'based on the applicable laws of your country or state'. I treated a jurisdiction-conditional legal right as not documented.

10. Training or sale does not override patient choiceYesdocumented
Not independently replicated
Your prompts, data and outputs never train anything of ours. Source

This is the home page Trust & provenance claim. The privacy notice says only that Noah may use data 'for undertaking internal research for technological development and demonstration' and has an unspecific AI opt-out in account settings. The privacy notice does not contradict the home claim but does not repeat it.

11. Patient can run it or take it elsewhereNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Vendor-hosted only. Enterprise deployments run models in the customer's environment, which does not apply to individual users.

12. No advertising or data businessNodocumented
Not independently replicated
We also permit third parties and service providers to use online tracking technologies on our Services for analytics and advertising Source

The privacy notice also lists Ad Networks, Retargeting Platforms and Affiliate Marketing Programs among third-party categories. It says no personal information was sold or shared in the last 12 months.

Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.

Checklist rules · Independent review and limitations · Later evidence follow-up

Earlier v1.3 assessment and control finding

Historical assessment under different rules. It does not set the current checklist zone.

MixedEarlier review, before the published method. Documents only.

Agency finding, before method v1.3

Mixed

Legacy editorial placement, pre-method: 55

No eligible reviewer. This tool uses AI models from both companies whose models code HugoScore reviews, Anthropic and OpenAI, so neither may review it. Its finding and any number are editorial placements made before the method existed.

Evidence
Documentary review. Public sources only, no hands-on testing by HugoScore.
Review status
AI draft. No person has settled the findings.
The question we ask Who does Noah AI serve in this deployment?
Control Noah X, the publicly accessible Noah AI professional research agent, assessed for a patient's direct research use. Hypothetical downstream pharma-industry effects are not scored.
Agency read Mixed
Vendor
TOLONGEVITY PTE. LTD. (dba Noah AI)
Who it serves
Patient-accessible research AI with professional and institutional uses
Primary User
Biopharma professionals, biotech investors, consultants, clinicians, and researchers; patients, caregivers, and medical students as a secondary public audience
Control Model
Vendor-hosted public service. Controls and downstream processors depend on the assessed deployment.
Patient Impact
Citations and downloadable interim analysis can help users challenge framing and conclusions. The baseline's assertion that nothing supports patient action is too absolute: research can support a patient's chosen action without a dedicated appointment or appeal feature.
Profile Status
Document-based draft
Last assessed
Oct 30, 2026
Earlier review confidence
Low to medium, primary documents only (AI-assisted draft)
Earlier review model
OpenAI Codex / GPT-6
Earlier human review record
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Earlier evidence and assessment

The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.

Earlier finding · Legacy editorial placement, pre-method: 55

Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 55. Not comparable with v1.3 positions.

Mixed

Noah AI supports direct research questions, scope clarification, and editable evidence. These patient-accessible functions must be distinguished from inferred institutional uses. The evidence does not establish universal absence of recourse or dominant downstream effects.

Patient agency

How this tool changes agency

Expands agency when

Citations and downloadable interim analysis can help users challenge framing and conclusions. The baseline's assertion that nothing supports patient action is too absolute: research can support a patient's chosen action without a dedicated appointment or appeal feature.

Limits agency when

Direct patient experience, clinical boundaries inside the app, processor terms, research-input use and actual institutional deployments remain unknown.

Patient agency assessment

Who sets and changes the goal?

Patient authority

In direct use, patients can define research goals and constraints and take editable evidence away. Professional market positioning does not erase that authority. Patients affected by another organization's analysis are a different deployment and cannot be assigned a blanket lack of recourse without evidence.

What can the patient understand, question, or do?

Critical capacity

Citations and downloadable interim analysis can help users challenge framing and conclusions. The baseline's assertion that nothing supports patient action is too absolute: research can support a patient's chosen action without a dedicated appointment or appeal feature.

Can the patient evaluate the conditions of use?

Informed control

The policy remains poorly specific about sensitive research inputs and model recipients. Distinguish documented advertising categories from an unsupported claim that health prompts are disclosed to them. Search absence cannot confirm that independent evidence does not exist.

Text findings

Conditions of use

Published controls and their limits

The policy remains poorly specific about sensitive research inputs and model recipients. Distinguish documented advertising categories from an unsupported claim that health prompts are disclosed to them. Search absence cannot confirm that independent evidence does not exist.

What remains unknown?

Not tested or not established

Direct patient experience, clinical boundaries inside the app, processor terms, research-input use and actual institutional deployments remain unknown.

Who evaluated this?

AI-assisted public-source draft

Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.

Sources checked

Source-specific findings and retrieval limitations are recorded in the full report.

Earlier review provenance

Criteria

CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.

Reviewer

AI-assisted public-source reassessment prepared in OpenAI Codex.

AI / model

OpenAI Codex / GPT-6

Human review

Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Review date

2026-09-08

Limitations

Direct patient experience, clinical boundaries inside the app, processor terms, research-input use and actual institutional deployments remain unknown. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.

Earlier review method

Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.

Document-based draft · Low to medium, primary documents only (AI-assisted draft)